BiotechFinances
GLIOBLASTOMA: "A CHALLENGE TWICE AS DEMANDING, BUT WORTH IT"

GLIOBLASTOMA: "A CHALLENGE TWICE AS DEMANDING, BUT WORTH IT"

January 23, 2026

Translated by artificial intelligence from the original French version. Learn more

On the occasion of the Deeptech in Glioblastoma (GBM) symposium organized this Thursday by the Paris-Saclay Cancer Cluster (PSCC) and the Brain&Mind Institute in Villejuif, Biotech Finances interviewed Dr. Sandrine Courtès, founder and CEO of Lab2Biotech and committed to the fight against GBM. Market, innovation, clinical trials, funding

: an overview of a segment of neuro-oncology that is both narrow, risky, and strategic.

Biotech Finances: You have a dual background in science and business, and a strong personal connection to glioblastoma. How d...

Written byJacques-Bernard TASTEBIOTECHFINANCES

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.

Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit.

At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt.

Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum.

Subscribe

Read more...

This is a standard plan article, subscribe to access the full content

GLIOBLASTOMA: "A CHALLENGE TWICE AS DEMANDING, BUT WORTH IT" | BiotechFinances